CyberKnife for Unresectable Renal Tumors

Status Completed

Clinical Trial Summary

This is a dose escalation study using the CyberKnife radiotherapy device for small surgical or medically untreatable renal tumors. Patients with renal tumors 5cms or less in diameter will be accrued onto this study. The ability of CyberKnife to ablate these renal tumors and maintain renal function with dose escalation will be assessed.

Clinical Trial Description

The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delivers radiation using a precise targeting methodology allowing a focal treatment margin around the target, thus limiting the volume of adjacent tissue receiving high doses radiation. This in turn allows the delivery of high doses of radiation to the prostate over a short series of treatments. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00807339
Study type	Interventional
Source	Beth Israel Deaconess Medical Center
Contact
Status	Completed
Phase	N/A
Start date	March 2006
Completion date	August 20, 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03634540` - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)	Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT00531284` - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05842044` - NSAID Use After Robotic Partial Nephrectomy	Phase 2
Recruiting	`NCT05387863` - Decision Aid (DA) for Renal Patients	N/A
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Completed	`NCT04933604` - LPN in Patients With High-complex Renal Tumors
Withdrawn	`NCT03390413` - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer	N/A
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT03203473` - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)	Phase 2
Suspended	`NCT04115254` - Stereotactic Magnetic Resonance Guided Radiation Therapy	N/A
Enrolling by invitation	`NCT02609269` - Decipher Genomics Resource for Intelligent Discovery
Completed	`NCT01444456` - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia	N/A
Terminated	`NCT01453595` - BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)	Phase 1/Phase 2
Completed	`NCT02811250` - Stereotactic Radiotherapy for Renal Cancers	N/A
Completed	`NCT00398814` - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers	Phase 1
Completed	`NCT00399152` - Perifosine + Sunitinib Malate for Patients With Advanced Cancers	Phase 1
Completed	`NCT00458536` - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF	Phase 1/Phase 2
Recruiting	`NCT03693014` - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors	Phase 2
Completed	`NCT00418496` - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma	Phase 1